[Lambert-Eaton myasthenic syndrome: response to treatment with 3,4-diaminopyridine].
Morata
C
C
Alfaro
A
A
Chumillas
M J
MJ
Montalar
J
J
D015761:4-Aminopyridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000077770:Amifampridine; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000150:complications / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D015221:Potassium Channels; D012074:Remission Induction
D015221:Potassium Channels; D015761:4-Aminopyridine; D000077770:Amifampridine
Síndrome miasténico de Lambert-Eaton: respuesta al tratamiento con 3,4-diaminopiridina.